Immune Pharmaceuticals Inc (fka IMNPQ)

[Investor100]

Immune Pharmaceuticals Announces Immuno-Oncology R&D Update on December 8, 2016

Discussion on the topics listed below is what I anticipate on the Facebook platform discussion!

http://www.prnewswire.com/news-releases/immune-pharmaceuticals-announces-immuno-oncology-rd-update-on-december-8-2016-300367275.html

Confirms plans for pivotal phase 3 Overall Survival study with Ceplene in AML

NEW YORK, Nov. 22, 2016 /PRNewswire/ -- Immune Pharmaceuticals (NASDAQ: IMNP) (Immune) announced today that it will hold an Immuno-Oncology R&D Update for investors on December 8, 2016 in New York City. Immune management and several Oncology Key Opinion leaders will review development plans and milestones for Ceplene® and other pipeline assets to be funded separately in the recently announced Immune subsidiary, Cytovia Oncology.

Prior to the Immuno-Oncology R&D Update, the Ceplene Scientific Advisory Board (SAB) will meet on December 4, 2016 in San Diego where the American Society of Hematology is holding its annual meeting. Following the guidance from the Food and Drug Administration, the SAB will review the proposed clinical protocol for a pivotal phase 3 Overall Survival clinical study of Ceplene in combination with low dose IL2 in the remission maintenance of patients with Acute Myeloid Leukemia (AML).

Investor 100